Literature DB >> 8739470

Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.

K A Alanen1, T Kuopio, P J Koskinen, T J Nevalainen.   

Abstract

Immunohistochemical detection of prostate specific antigen (PSA) in metastases of adenocarcinomas is widely used as an aid to identify the prostatic origin of metastatic cells. However, on the one hand, PSA may not be expressed in some poorly differentiated prostatic carcinomas, while on the other, PSA immunoreactivity has been found in small amounts in non-prostatic tissues. The aim of the current study was to evaluate the prevalence of PSA immunoreactivity in normal non-prostatic tissues and in breast carcinoma. PSA was localized by immunohistochemistry with four commercial antibodies in 34 different normal human tissues, and in 15 ductal and seven apocrine breast carcinomas. Concentrations of PSA in tissue homogenates of prostate and nine non-prostatic tissues from autopsied subjects were measured by a two-site immunoradiometric assay. Weak PSA immunoreactivity was found by immunohistochemistry in kidney, parotid gland and pancreatic tissues. Variable PSA immunoreactivity was seen in three cases of ductal (20%) and two cases of apocrine breast carcinoma (28%). No consistent PSA immunoreactivity was found in homogenates of non-prostatic tissues by the immunoradiometric assay. We conclude that PSA is a quite specific marker of prostatic tissue. However, there are some non-prostatic neoplastic and normal tissues that express PSA. Therefore, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of immunolabelling for PSA alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739470     DOI: 10.1016/S0344-0338(96)80226-3

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

Review 1.  Metastasis of occult prostatic carcinoma to the sphenoid sinus: report of a rare case and a review of the literature.

Authors:  Fredrik Petersson; Tan Sien Hui; David Loke; Thomas Choudary Putti
Journal:  Head Neck Pathol       Date:  2011-11-05

Review 2.  [Diagnosis and prognosis of salivary gland tumors. An interpretation of new revised WHO classification].

Authors:  G Seifert
Journal:  Mund Kiefer Gesichtschir       Date:  1997-09

Review 3.  Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.

Authors:  T J Wallace; T Torre; M Grob; J Yu; I Avital; Bldm Brücher; A Stojadinovic; Y G Man
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

Review 4.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

5.  Expression of androgen receptor and prostate-specific antigen in male breast carcinoma.

Authors:  Noman Kidwai; Yun Gong; Xiaoping Sun; Charuhas G Deshpande; Anjana V Yeldandi; M Sambasiva Rao; Sunil Badve
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

6.  Clinical significance of serum PSA in breast cancer patients.

Authors:  Toru Hanamura; Koichi Ohno; Shinya Hokibara; Hideki Murasawa; Toshitsugu Nakamura; Hidehiko Watanabe; Machiko Kaizuka; Shinji Sawano; Hiroshi Koyama; Ken-Ichi Ito
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

7.  New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers.

Authors:  Karin Ried; Tasnuva Tamanna; Sonja Matthews; Peter Eng; Avni Sali
Journal:  Front Oncol       Date:  2020-04-23       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.